---
title: "Maravai LifeSciences Holdings, Inc. (MRVI.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MRVI.US.md"
symbol: "MRVI.US"
name: "Maravai LifeSciences Holdings, Inc."
industry: "Life Sciences Tools and Services"
datetime: "2026-05-19T20:26:43.829Z"
locales:
  - [en](https://longbridge.com/en/quote/MRVI.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MRVI.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MRVI.US.md)
---

# Maravai LifeSciences Holdings, Inc. (MRVI.US)

## Company Overview

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples.

| Item | Detail |
|------|--------|
| Industry | Life Sciences Tools and Services |
| Exchange | US Market |
| Website | [www.maravai.com](https://www.maravai.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:12.000Z

**Overall: D (0.69)**

**Industry**: Life Sciences Tools and Services

| Metric | Value |
|--------|-------|
| Industry Ranking | 45 / 59 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -15.35% |  |
| Net Profit YoY | 35.74% |  |
| P/B Ratio | 4.96 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1048834347.36 |  |
| Revenue | 204730000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -40.83% | E |
| Profit Margin | -51.07% | E |
| Gross Margin | 51.19% | B |
| Revenue YoY | -15.35% | E |
| Net Profit YoY | 35.74% | B |
| Total Assets YoY | -25.69% | E |
| Net Assets YoY | -30.40% | E |
| Cash Flow Margin | 37.79% | D |
| OCF YoY | -15.35% | E |
| Turnover | 0.24 | D |
| Gearing Ratio | 48.25% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Maravai LifeSciences Holdings, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-15.35%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "35.74%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.96",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "1048834347.36",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "204730000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-40.83%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-51.07%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "51.19%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-15.35%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "35.74%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-25.69%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-30.40%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "37.79%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-15.35%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.24",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "48.25%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -10.03 | 49/59 | - | - | - |
| PB | 4.96 | 43/59 | 3.85 | 2.55 | 1.88 |
| PS (TTM) | 5.12 | 40/59 | 4.82 | 3.10 | 2.33 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | ChromaDex (CDXC.US) | A | A | A | B | A | A |
| 02 | Agilent Tech (A.US) | A | C | B | C | C | B |
| 03 | West Pharmaceutical (WST.US) | B | B | B | B | B | B |
| 04 | Illumina (ILMN.US) | A | C | B | D | C | B |
| 05 | WuXi Biologics (WXXWY.US) | B | B | C | A | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-13T04:00:00.000Z

Total Analysts: **9**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 56% |
| Hold | 4 | 44% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.22 |
| Highest Target | 5.00 |
| Lowest Target | 4.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/MRVI.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/MRVI.US/norm.md)
- [Related News](https://longbridge.com/en/quote/MRVI.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/MRVI.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**